Utility of ¹⁸F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.

ABSTRACT:

Background

Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of ¹⁸F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2-negative breast cancer.

Methods

AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment ¹⁸F-FDG PET/CT and clinical outcomes including pathologic response to NAC were e

SUBMITTER: Lee IH 

PROVIDER: S-EPMC7667770 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature